Physician profile

Dana L Simpson

Family · Chattanooga, TN

NPI 1114253689

$11,360.92

in general payments reported to CMS, 2019-2025

39 companies · $5,216 in 2025

The $5,216 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).

See the full distribution for Family

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,895.43
Travel and Lodging$2,761.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $3,132.32 2021-2025 Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management
Medtronic, INC. $2,760.41 2021-2025 Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim
Abbott Laboratories $950.40 2021-2025 Eterna
Abbvie INC. $619.54 2021-2025
Nevro Corp. $386.90 2021-2024 Senza
Scilex Pharmaceuticals INC. $320.03 2021-2025 Ztlido
Collegium Pharmaceutical, INC. $298.80 2021-2025 Xtampza, Belbuca
Relievant Medsystems, INC. $279.14 2023 Intracept
Saluda Medical Americas, INC. $254.23 2024-2025 Evoke
Protega Pharmaceutials INC $224.07 2022-2023 Roxybond
Nalu Medical, INC. $220.14 2022-2023 Nalu Neurostimulation System
Vertos Medical, INC. $155.27 2022-2024 Mild Device Kit
Biohaven Pharmaceuticals, INC. $154.15 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $152.71 2021-2022
Pfizer INC. $149.43 2021-2025
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Mml US, INC. $141.18 2025 Reactiv8
Biohaven Pharmaceutical Holding Company LTD. $130.00 2022
Allergan, INC. $125.23 2021-2022
Spinal Simplicity, LLC $102.91 2021-2022
Almatica Pharma LLC $96.45 2021-2022
Tersera Therapeutics LLC $96.05 2022-2025 Prialt
Arbor Pharmaceuticals, INC. $82.63 2021-2022
Grt US Holding, INC. $66.90 2021-2022
Avanos Medical $52.47 2024 Coolief* Cooled Radiofrequency
Ipsen Biopharmaceuticals, INC $50.72 2022-2025 Dysport
Pacira Therapeutics, INC. $35.82 2021
Fidia Pharma USA INC. $35.32 2024-2025 Hymovis
Merck Sharp & Dohme LLC $32.83 2022-2023 Belsomra
Redhill Biopharma INC. $31.98 2021
Azurity Pharmaceuticals, INC. $31.25 2024 Horizant
Horizon Therapeutics Plc $30.17 2021-2022
Globus Medical, INC. $27.88 2025 Senza
Merz Pharmaceuticals, LLC $24.78 2022
Pacira Pharmaceuticals Incorporated $24.72 2024 Iovera, Zilretta
Si-Bone, INC. $23.62 2025
Biotronik Nro, INC. $16.70 2025 Prospera
Ibsa Pharma INC. $16.34 2024 Licart, Tirosint
Supernus Pharmaceuticals, INC. $14.53 2021
Biodelivery Sciences International, INC. $12.90 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dana L Simpson

$11,360.92

in general payments reported 2019-2025

Years
2021-2025
Top company
Boston Scientific Corporation
Context
The $5,216 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/10848414/dana-l-simpson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.